US Patent

US11597692 — Process for preparing tapinarof

Composition of Matter · Assigned to Dermavant Sciences GmbH · Expires 2038-11-13 · 12y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects processes for preparing tapinarof, including novel intermediates and crystal forms, as well as pharmaceutical compositions containing tapinarof.

USPTO Abstract

The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.

Drugs covered by this patent

Patent Metadata

Patent number
US11597692
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-11-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Dermavant Sciences GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.